Announcement • May 29
Polaryx Therapeutics, Inc. announced that it has received $10.010784 million in funding Polaryx Therapeutics, Inc. announced that it has entered into a Securities Purchase Agreement issued 2,502,696 shares of common stock at a price of $4 per share for gross proceeds of $10,010,784 on May 28, 2026. MStone Partners Healthcare Limited, the Company’s largest stockholder, purchased 88,453 shares of common stock in the Private Placement, for gross proceeds to the Company of $360,000 Announcement • Apr 24
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial Polaryx Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to PLX-200 for the treatment of Juvenile Neuronal Ceroid Lipofuscinosis (JNCL/CLN3 disease), Krabbe disease (globoid cell leukodystrophy), and Sandhoff disease (GM2 gangliosidosis Type II). Following the March 2026 grant of FTD to PLX-200 in treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease), PLX-200 now holds FTD for all four prospective indications to be studied in the SOTERIA Phase 2 basket trial. The Fast Track program is designed to facilitate and expedite the review of therapies intended to treat serious or life-threatening conditions with unmet medical need. Companies receiving Fast Track Designation may benefit from more frequent interactions with the FDA and the potential for rolling review of a future marketing application. CLN2 disease, CLN3 disease, Krabbe disease, and Sandhoff disease are devastating neurodegenerative conditions with limited or no disease-modifying treatment options. The regulatory alignment received from the FDA’s Fast Track Designations highlight the seriousness of these disorders and the need for new therapeutic options like PLX-200. SOTERIA is a Phase 2, open-label, single arm trial intended to assess the safety, tolerability, and clinical activity of Polaryx’s lead drug candidate, PLX-200, in CLN2, CLN3, Krabbe disease, and Sandhoff disease, four different LSDs whose patient populations Polaryx believes represent approximately one quarter of the LSD population. SOTERIA is designed to be flexible, resource-efficient, and provide important data and information important to PLX-200’s future clinical development. Polaryx received a safe to proceed letter in October 2025 from the FDA and plans to initiate SOTERIA in the second half of 2026 in trial sites in the United States as well as in Europe and Asia or other foreign jurisdictions. Designed with a high degree of flexibility, SOTERIA represents a resource-efficient opportunity to validate PLX-200’s preclinical science across multiple LSDs while gathering data that will be invaluable in planning PLX-200’s future development pathway, including the initiation of potentially pivotal trials. For the CLN2 and CLN3 cohorts, although the entire trial is open label, these cohorts will incorporate analyses comparing natural history data as a control arm to PLX-200’s treated arm. A natural history study is a preplanned observational study intended to track the course of the disease. Should the data demonstrate compelling clinical activity, Polaryx may seek conditional marketing authorization. Polaryx’s lead drug candidate, PLX-200, is an orally available compound comprised of gemfibrozil. Gemfibrozil is an FDA-approved lipid regulating agent in the fibrate family which has only been approved in a capsule form for adult patients with very high elevations of serum triglyceride levels to decrease serum triglycerides and very low-density lipoprotein cholesterol and increase high density lipoprotein cholesterol. The ability of gemfibrozil to cross the blood-brain barrier (BBB) has also been documented in third-party preclinical trials and safe use of gemfibrozil in adults has also been well-established over several decades of clinical investigation and commercial use, which the company believes accelerates clinical development and reduces associated costs. The company believes the unique ability of PLX-200 to cross the BBB, along with its widely applicable mechanism of action, positions PLX-200 to potentially address the immense unmet need in multiple rare, catastrophic LSD indications. Announcement • Mar 18
Polaryx Therapeutics Inc Receives FDA Fast Track Designation For PLX-200 For Late-Infantile Neuronal Ceroid Lipofuscinosis CLN2 Disease Polaryx Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PLX-200 for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease). The Fast Track program is designed to facilitate and expedite the review of therapies intended to treat serious or life-threatening conditions with unmet medical need. Companies receiving Fast Track designation may benefit from more frequent interactions with the FDA and the potential for rolling review of a future marketing application. Polaryx continues to advance the development of PLX-200 through SOTERIA, a phase 2, open-label, single-arm basket trial designed to evaluate the safety, tolerability, and clinical activity of PLX-200 across four rare lysosomal storage disorders: CLN2, CLN3, Krabbe disease, and Sandhoff disease. 
